Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Gastric Cancer · Gastro-esophageal Junction Cancer · Pancreatic Ductal Adenocarcinoma · Esophageal Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 392 (planned)
- Started
- Jul 11, 2023
- Main results expected
- Mar 16, 2029
- Fully finished
- Mar 16, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The number of patients with adverse events
Measured over: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with adverse events of special interest
Measured over: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.
Measured over: From first dose of study drug until the end of Cycle 1
The number of patients with serious adverse events
Measured over: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
Objective Response Rate (ORR)
Measured over: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06005493 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC